Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E116.20 EPS (ttm)1.60 Insider Own0.20% Shs Outstand247.58M Perf Week-0.11%
Market Cap45.91B Forward P/E39.93 EPS next Y4.64 Insider Trans-48.03% Shs Float247.58M Perf Month5.49%
Income415.10M PEG2.25 EPS next Q1.02 Inst Own98.10% Short Float1.16% Perf Quarter2.39%
Sales2.62B P/S17.51 EPS this Y327.00% Inst Trans0.13% Short Ratio2.51 Perf Half Y13.52%
Book/sh10.57 P/B17.54 EPS next Y22.50% ROA11.00% Target Price198.27 Perf Year19.88%
Cash/sh11.18 P/C16.59 EPS next 5Y51.63% ROE18.60% 52W Range136.50 - 194.92 Perf YTD23.75%
Dividend- P/FCF64.58 EPS past 5Y47.60% ROI8.80% 52W High-4.86% Beta1.58
Dividend %- Quick Ratio3.60 Sales past 5Y10.30% Gross Margin87.30% 52W Low35.86% ATR4.61
Employees2300 Current Ratio3.70 Sales Q/Q-40.20% Oper. Margin3.90% RSI (14)54.07 Volatility3.71% 2.36%
OptionableYes Debt/Eq0.22 EPS Q/Q-24.20% Profit Margin15.80% Rel Volume0.97 Prev Close177.65
ShortableYes LT Debt/Eq0.22 EarningsOct 24 AMC Payout0.00% Avg Volume1.14M Price185.45
Recom1.80 SMA200.71% SMA502.68% SMA20011.43% Volume1,136,652 Change4.39%
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Jul-11-17Initiated Jefferies Buy
Jun-23-17Upgrade Needham Hold → Buy $155
Jun-02-17Upgrade Oppenheimer Perform → Outperform
Mar-31-17Upgrade Maxim Group Hold → Buy $143
Mar-17-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Mar-09-17Initiated UBS Buy $106
Oct-16-18 04:01PM  Vertex to Announce Third Quarter 2018 Financial Results on October 24 Business Wire
Oct-12-18 02:23PM  3 High-Reward Stocks From 3 Emerging Trends InvestorPlace
12:48PM  FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial American City Business Journals
Oct-11-18 08:49AM  Why CRISPR Therapeutics Stock Is Heading Higher Today Motley Fool
06:25AM  CRISPR Therapeutics Set to Surge After FDA Lifts Hold on Human Trial Investopedia
Oct-10-18 05:11PM  After-hours buzz: SQ, FLR & more CNBC
05:03PM  FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial American City Business Journals
04:12PM  Crispr stock up 8% as company says FDA accepted new-drug application MarketWatch
04:01PM  CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
10:10AM  Why the Earnings Surprise Streak Could Continue for Vertex (VRTX) Zacks
Oct-09-18 09:41AM  3 Biotech Stocks With Major Incoming Catalysts Motley Fool
Oct-05-18 02:53PM  7 Fast-Growing Stocks to Buy Today InvestorPlace
Oct-01-18 08:02AM  Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines Business Wire
Sep-28-18 08:16AM  Better Buy: Vertex Pharmaceuticals Incorporated vs. Galapagos NV Motley Fool
Sep-26-18 04:19PM  Here's Why The Stock Market Sold Off After The Fed Meeting Investor's Business Daily
03:59PM  Stock News Today: Biotechs Help Nasdaq 100 To Day Of Outperformance Investor's Business Daily
Sep-16-18 08:31AM  Is CRISPR Therapeutics AG a Buy? Motley Fool
Sep-12-18 06:01AM  3 Top Healthcare Stocks to Buy in September Motley Fool
Sep-11-18 04:01PM  Vertex to Present at the Morgan Stanley Healthcare Conference on September 14 Business Wire
Sep-10-18 09:11AM  Vertex Appoints Katharine Jensen as Head of Corporate Social Responsibility Business Wire
Sep-07-18 10:45AM  Vertex Completes Enrollment in Triple Combination Studies Zacks
08:58AM  Lilly, Teva, Pfizer & Others Await FDA Decisions in September Zacks
Sep-06-18 08:52AM  The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals Zacks
08:00AM  Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis Business Wire
Sep-05-18 09:39AM  Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars Zacks
09:16AM  Forget CRISPR Therapeutics: Vertex Pharmaceuticals Incorporated Is a Better Biotech Stock Motley Fool
Sep-04-18 09:45AM  An Apple A Day Can't Keep Strong Gains Away From These 5 Hot Medical Stocks Investor's Business Daily
09:40AM  Vertex Inks Reimbursement Agreement for Orkambi in Australia Zacks
Sep-03-18 03:00AM  Vertex Announces Reimbursement Agreement in Australia for ORKAMBI® (lumacaftor/ivacaftor) for People with Cystic Fibrosis Ages Six Years and Older with Two Copies of the F508del Mutation Business Wire
Sep-02-18 09:10AM  3 Biotech Stocks That Could Soar Next Week Motley Fool
01:00AM  Vertex's Cystic Fibrosis Medicine to Be Subsidized in Australia Bloomberg
Sep-01-18 12:00PM  3 Stocks That Could Put Netflix's Returns to Shame Motley Fool
Aug-31-18 11:34AM  Vertex Inks Deal With Genomics to Make Serious Disease Drugs Zacks
Aug-30-18 09:39AM  Vertex (VRTX) Hits Fresh High: Is There Still Room to Run? Zacks
08:02AM  The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration Benzinga
02:00AM  Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines Business Wire
Aug-24-18 11:46AM  Why Is Vertex (VRTX) Up 0.1% Since Last Earnings Report? Zacks
08:16AM  3 Relatively Safe Ways to Invest in Gene Editing Motley Fool
Aug-23-18 09:18AM  4 Biotech Stocks Investors Can Bet on Post Solid Q2 Earnings Zacks
09:10AM  Mallinckrodt's Stannsoporfin Gets Complete Response Letter Zacks
03:00AM  Vertex Appoints Ludovic Fenaux as Senior Vice President, International Commercial Operations Business Wire
Aug-22-18 11:43AM  Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco Zacks
10:15AM  Stocks Lower Amid Trump Troubles; This Top Retail Stock Breaks Out Investor's Business Daily
Aug-21-18 04:01PM  IBD Stock Of The Day: Vertex Pharma Nears Third Breakout Of 2018 Investor's Business Daily
08:32AM  Looking for a Growth Stock? Why It is Time to Focus on Vertex Pharmaceuticals (VRTX) Zacks
Aug-20-18 04:47PM  Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin Zacks
08:45AM  Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International Zacks
Aug-17-18 09:44AM  4 Winning Stocks With Solid Efficiency Level Zacks
08:53AM  Should Vertex Pharmaceuticals (VRTX) Be On Your Radar Now? Zacks
Aug-16-18 10:04AM  Vertex Awards Two College Students Full Scholarships to the University of Massachusetts Business Wire
09:07AM  Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children Zacks
Aug-15-18 04:39PM  Vertex cystic fibrosis drug gets expanded approval for use in infants Reuters
03:29PM  FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene Business Wire
08:48AM  The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue Benzinga
Aug-14-18 10:55AM  Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit Zacks
Aug-13-18 01:26PM  The Week Ahead: Nvidia, Retailer Earnings In Focus Benzinga
Aug-10-18 07:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Immunomedics, Vertex Pharmaceuticals, Ralph Lauren, Alliant Energy, TreeHouse Foods, and Lincoln National New Research Emphasizes Economic Growth GlobeNewswire
Aug-09-18 10:15AM  7 Biotech Stocks With Big Upcoming Catalysts Kiplinger
10:00AM  Is Crispr Therapeutics Stock Grossly Overvalued? Motley Fool
09:27AM  Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2 Zacks
09:17AM  Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise Zacks
Aug-08-18 04:18PM  3 Top Biotech Stocks to Buy in August Motley Fool
10:49AM  Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2 Zacks
07:52AM  Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges Zacks
Aug-07-18 03:48PM  FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease Business Wire
03:32PM  8 Biotechs Still Worth Buying After a Sector Surge Barrons.com
Aug-06-18 04:00PM  This stock sector most often beats analysts estimates MarketWatch
03:30PM  The Week Ahead: Earnings From Disney, Roku And Snap, Rite Aid Votes On Albertsons Deal Benzinga
Aug-03-18 03:09PM  Why Boston and central Texas have so many of the best-paying companies in the U.S. Here's where other cities are missing out. American City Business Journals
Aug-02-18 10:35AM  Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track Zacks
08:00AM  Celtaxsys cystic fibrosis drug reduces key symptom in mid-stage study Reuters
Aug-01-18 09:34AM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit Zacks
Jul-31-18 07:39AM  9 Near-Monopolies That Are Legal in America Motley Fool
Jul-30-18 11:24PM  Edited Transcript of VRTX earnings conference call or presentation 25-Jul-18 8:30pm GMT Thomson Reuters StreetEvents
01:47PM  Here's Why Vertex Pharmaceuticals Earnings Are Growing Faster Than Revenue Motley Fool
12:09PM  Could Gilead Merge With Pfizer Or Vertex To Solve Its CEO Problem? Investor's Business Daily
Jul-27-18 10:22AM  Vertex Receives European CHMP Positive Opinion for SYMKEVI® (tezacaftor/ivacaftor) for People with Cystic Fibrosis Aged 12 and Older with Certain Mutations in the CFTR Gene Business Wire
10:19AM  3 Reasons Why Vertex Pharmaceuticals Stock Isn't Nearly as Expensive as It Looks Motley Fool
Jul-26-18 02:42PM  Vertex and Alexion Are Schooling Big Biotech Bloomberg
02:34PM  Vertex Pharmaceuticals (VRTX) Q2 2018 Earnings Conference Call Transcript Motley Fool
01:40PM  Vertex says sales of cystic fibrosis drugs could hit $3B this year American City Business Journals
01:23PM  MARKETS: Facebook aside, earnings are rolling in positive and boosting stocks Yahoo Finance Video
11:51AM  Vertex (VRTX) Q2 Earnings and Revenues Surpass Estimates Zacks
Jul-25-18 04:10PM  Vertex: 2Q Earnings Snapshot Associated Press
04:01PM  Vertex Reports Second-Quarter 2018 Financial Results Business Wire
02:30PM  Vertex Pharmaceuticals Incorporated to Host Earnings Call ACCESSWIRE
01:10PM  3 'Strong Buy' Healthcare Stocks Poised to Surge TheStreet.com
08:27AM  Earnings Preview For Vertex Pharmaceuticals Benzinga
07:45AM  Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks ACCESSWIRE
Jul-24-18 03:24PM  4 of the Best U.S. Stocks to Buy Today for Long-Term Growth InvestorPlace
08:37AM  Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK Zacks
Jul-23-18 11:06AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Jul-20-18 06:00AM  7 High Return Stocks for Your Portfolio Investopedia
Jul-16-18 01:05PM  CRISPR Therapeutics Stock History: The Rise of the World's Biggest Gene-Editing Biotech Motley Fool
Jul-12-18 04:01PM  Vertex to Announce Second Quarter 2018 Financial Results on July 25 Business Wire
Jul-08-18 03:15PM  Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far Motley Fool
Jul-05-18 02:40PM  Drug pricing debate could heat up in July CNBC Videos
Jul-02-18 10:06AM  Company News For Jul 2, 2018 Zacks
09:02AM  Vertex's Shares Rally as a Rival's CF Candidate Disappoints Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Acceleron Pharma and Vertex Pharmaceuticals ACCESSWIRE
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parini MichaelEVP, CL&AOOct 12Option Exercise90.292,125191,86641,734Oct 16 04:29 PM
Parini MichaelEVP, CL&AOOct 12Sale177.202,125376,55039,609Oct 16 04:29 PM
Kewalramani ReshmaEVP and CMOOct 08Sale186.952,305430,9201,909Oct 09 04:50 PM
Parini MichaelEVP, CL&AOOct 04Option Exercise122.454,250520,41343,859Oct 05 05:35 PM
Parini MichaelEVP, CL&AOOct 04Sale191.584,250814,21539,609Oct 05 05:35 PM
Bhatia Sangeeta N.DirectorOct 03Option Exercise126.386,818861,6509,579Oct 05 05:28 PM
Bhatia Sangeeta N.DirectorOct 03Sale192.136,8181,309,9424,879Oct 05 05:28 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Option Exercise155.572,445380,36941,558Oct 02 04:30 PM
Graney ThomasChief Financial OfficerOct 01Sale193.241,076207,92612,430Oct 02 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Sale194.622,445475,84639,113Oct 02 04:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Option Exercise131.892,125280,26641,238Aug 30 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Sale181.892,125386,51639,113Aug 30 04:07 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Option Exercise103.095,803598,21152,555Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 03Option Exercise86.5280969,99516,896Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Option Exercise86.522,330201,59241,443Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 03Option Exercise86.521,942168,02248,604Aug 06 06:19 PM
Parini MichaelEVP, CL&AOAug 03Option Exercise86.522,330201,59241,939Aug 07 04:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Sale174.205,8031,010,88346,752Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 03Sale174.20809140,92816,087Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Sale174.202,330405,88639,113Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 03Sale175.101,942340,05046,662Aug 06 06:19 PM
Parini MichaelEVP, CL&AOAug 03Sale174.202,330405,88639,609Aug 07 04:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Option Exercise111.334,280476,47948,907Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 02Option Exercise91.051,289117,36317,376Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Option Exercise91.051,796163,52640,909Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 02Option Exercise91.052,155196,21348,817Aug 06 06:19 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Sale176.784,280756,61646,752Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 02Sale174.591,289225,04716,087Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Sale174.591,796313,56439,113Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 02Sale176.732,155380,85246,662Aug 06 06:19 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Option Exercise96.872,125205,84948,877Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Option Exercise96.871,719166,52048,381Jul 17 06:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Option Exercise131.8923,3753,082,92962,488Jul 18 05:32 PM
Silva Paul MSVP & Corp ControllerJul 16Option Exercise96.8786083,30816,947Jul 18 05:44 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Sale179.852,125382,18146,752Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Sale180.361,719310,04246,662Jul 17 06:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Sale182.0023,3754,254,25039,113Jul 18 05:32 PM
Silva Paul MSVP & Corp ControllerJul 16Sale179.85860154,67116,087Jul 18 05:44 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Option Exercise131.896,375840,79953,127Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 13Option Exercise96.8712,0311,165,44358,693Jul 17 06:30 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Sale179.006,3751,141,12546,752Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 13Sale180.0012,0312,165,58046,662Jul 17 06:30 PM
Silva Paul MSVP & Corp ControllerJul 12Option Exercise90.2986077,64916,947Jul 16 04:19 PM
Parini MichaelEVP, CL&AOJul 12Option Exercise90.292,125191,86641,734Jul 16 04:37 PM
Silva Paul MSVP & Corp ControllerJul 12Sale175.02860150,51716,087Jul 16 04:19 PM
Parini MichaelEVP, CL&AOJul 12Sale175.022,125371,91839,609Jul 16 04:37 PM
Parini MichaelEVP, CL&AOJul 05Option Exercise122.454,250520,41343,859Jul 09 06:14 PM
Parini MichaelEVP, CL&AOJul 05Sale168.384,250715,61539,609Jul 09 06:14 PM
Sachdev AmitEVP, CROJun 29Option Exercise88.904,096364,14850,758Jul 03 04:12 PM
Silva Paul MSVP & Corp ControllerJun 29Option Exercise91.502,957270,56917,376Jul 03 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 29Option Exercise89.153,708330,57850,460Jul 03 04:20 PM
SMITH IAN FEVP, COOJun 29Option Exercise131.8923,3753,082,92970,074Jul 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 29Option Exercise87.1313,4451,171,39783,444Jul 03 04:29 PM
Sachdev AmitEVP, CROJun 29Sale167.634,096686,61546,662Jul 03 04:12 PM
Silva Paul MSVP & Corp ControllerJun 29Sale166.522,957492,38516,087Jul 03 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 29Sale169.003,708626,65246,752Jul 03 04:20 PM
SMITH IAN FEVP, COOJun 29Sale166.3023,3753,887,17346,699Jul 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 29Sale164.9844,3317,313,59639,113Jul 03 04:29 PM
LEIDEN JEFFREY MCEO & PresidentJun 22Option Exercise83.36106,5008,877,840297,260Jun 26 05:18 PM
SMITH IAN FEVP, COOJun 22Option Exercise109.144,250463,84550,949Jun 26 05:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 22Option Exercise109.144,250463,84551,002Jun 26 05:20 PM
LEIDEN JEFFREY MCEO & PresidentJun 22Sale160.00140,21122,433,760157,049Jun 26 05:18 PM
SMITH IAN FEVP, COOJun 22Sale160.004,250680,00046,699Jun 26 05:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 22Sale159.004,250675,75046,752Jun 26 05:20 PM
Bhatia Sangeeta N.DirectorJun 04Sale152.05875133,0444,879Jun 05 05:39 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale155.789815,26669,999May 16 04:48 PM
Sachdev AmitEVP, CROMay 15Sale155.788312,93046,662May 16 05:06 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 15Sale155.7813821,49846,752May 16 05:11 PM
SMITH IAN FEVP, COOMay 15Sale155.7821733,80446,699May 16 05:21 PM
Parini MichaelEVP, CL&AOMay 15Sale155.788513,24139,609May 16 05:24 PM
Silva Paul MSVP & Corp ControllerMay 15Sale155.7820131,31216,087May 16 05:27 PM
Parini MichaelEVP, CL&AOMay 03Option Exercise86.522,330201,59241,939May 04 04:23 PM
Parini MichaelEVP, CL&AOMay 03Sale149.502,330348,33539,609May 04 04:23 PM
SMITH IAN FEVP, COOApr 26Option Exercise108.6553,1255,771,98999,824Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 26Option Exercise122.4538,2504,683,71377,859Apr 27 04:38 PM
SMITH IAN FEVP, COOApr 26Sale160.1253,1258,506,37546,699Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 26Sale159.5638,2506,103,17039,609Apr 27 04:38 PM
SMITH IAN FEVP, COOApr 25Option Exercise84.4514,1721,196,78678,667Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 25Option Exercise90.292,125191,86642,123Apr 27 04:38 PM
SMITH IAN FEVP, COOApr 25Sale155.3331,9684,965,52646,699Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 25Sale155.222,514390,23339,609Apr 27 04:38 PM
Silva Paul MSVP & Corp ControllerApr 18Option Exercise90.2985977,55916,946Apr 19 05:37 PM
Silva Paul MSVP & Corp ControllerApr 18Sale166.05859142,63716,087Apr 19 05:37 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 16Option Exercise96.872,125205,84948,877Apr 18 02:50 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 16Sale163.012,125346,39646,752Apr 18 02:50 PM
Silva Paul MSVP & Corp ControllerApr 02Sale161.213,438554,24916,087Apr 04 05:07 PM
Sachdev AmitEVP, CROMar 09Option Exercise96.8713,7501,331,96360,412Mar 12 05:36 PM
Sachdev AmitEVP, CROMar 09Sale175.0013,7502,406,25046,662Mar 12 05:36 PM
MCGLYNN MARGARET GDirectorMar 02Option Exercise81.5410,000815,40016,312Mar 05 06:13 PM
MCGLYNN MARGARET GDirectorMar 02Sale170.0010,0001,700,0006,312Mar 05 06:13 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 26Option Exercise86.521,554134,45253,211Feb 28 09:22 AM
Sachdev AmitEVP, CROFeb 26Option Exercise91.052,155196,21348,817Feb 28 09:30 AM
Sachdev AmitEVP, CROFeb 26Sale170.002,155366,35046,662Feb 28 09:30 AM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 26Sale169.006,4591,091,57146,752Feb 28 09:22 AM
Silva Paul MSVP & Corp ControllerFeb 20Sale158.493,437544,73019,525Feb 21 06:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 13Sale151.834,044614,00151,657Feb 15 04:23 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 12Sale152.826,8241,042,83355,701Feb 14 06:16 PM
Sachdev AmitEVP, CROFeb 12Sale150.8417,7962,684,41146,662Feb 14 06:23 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 12Sale150.825,122772,49369,663Feb 14 06:15 PM
LEIDEN JEFFREY MCEO & PresidentFeb 12Sale150.8323,9053,605,547190,658Feb 14 06:06 PM